Benjamin P. Saylor

“There is no clear evidence that adding metformin to standard of care increases overall survival in unselected patients with metastatic hormone-sensitive disease," said Silke Gillessen, MD.

Andrea Necchi, MD, reported that pCR was 42% (95% CI, 28-56) in cohort 1 and 23% (95% CI, 10-41) in cohort 2.

In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38, P = .002).

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD.

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001).

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD.

At a median follow-up of 44.8 months, median DFS in the pembrolizumab arm was 29.6 months vs 14.2 months in the observation arm.

The results “support the prioritized development of TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer," said Michiel van der Heijden, MD, PhD.

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm.

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD.

"These final analysis results of LITESPARK-005 support belzutifan as a treatment option in refractory kidney cancer after checkpoint inhibitor and VEGFR-TKI therapy," says Brian Rini, MD.

Urology Times’ exclusive survey reveals urologists/advanced practice providers’ thoughts on reusable vs disposable cystoscopes.

“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.

“For patients who received darolutamide plus ADT and docetaxel, minimal differences in post-progression survival were observed between first subsequent therapies," said Marc-Oliver Grimm, MD.

“Our results demonstrated that treatment with [the] Optilume BPH procedure resulted in significant symptom relief while still preserving erectile and ejaculatory function,” said Olivia Copelan, MD.

“We found that the SAPS is associated with higher intrarenal pressure and flow rate when compared to automated pumps," said Lucas B. Vergamini, MD.

Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.

The investigators found that the propulsion group had a 70% lower risk of relapse than the control group (HR 0.30, 95% CI: 0.13-0.68).

"[Nivolumab] plus [gemcitabine-cisplatin] showed significant and clinically meaningful benefit in OS, PFS, and response over [gemcitabine-cisplatin] alone," said Guru Sonpavde, MD.

"[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease," said Chiara Mercinelli, MD.

Qmax was also significantly improved, with a baseline of 7.7 mL/sec compared with 13.2 mL/sec at 4 years.

The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.

A late phase 3 trial evaluating the agent is underway at several clinics in Europe.

“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.

Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

The investigators reported that “the risk of recurrence was significantly lower following BLC (HR=0.67, 95% CI: 0.51-0.89) than WLC.”

The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).

At baseline, 16 patients had an IIEF-EF score of 11-21. These patients reported significant improvement in IIEF-EF score at Times 2 and 4, according to the authors.